Puma Biotechnology Q3 2026 Earnings: NERLYNX Growth Offset by Higher Costs

Puma Biotechnology (NASDAQ: PBYI) reported Q3 2026 total revenue of $55.1 million, up approximately 1.1% from $54.5 million a year earlier, while GAAP diluted EPS fell to $0.11 from $0.17. Increased U.S. demand supported NERLYNX product revenue, but lower royalty revenue and higher cost of sales and R&D spending reduced GAAP net income to $6.0 million, even as operating cash flow rose to $14.6 million.

Core Financial Results

Net product revenue increased 4.2% to $54.1 million, but total revenue rose only modestly because royalty revenue fell to $1.0 million from $2.6 million. Quarterly royalty revenue included a $2.1 million reduction from an accounting estimate change after third-party data showed generic NERLYNX products in China had reached a specified market-share threshold.

Total operating costs and expenses increased approximately 10.9% to $49.8 million. As a result, operating income and GAAP net income declined despite the higher product revenue. Non-GAAP adjusted net income, which excludes stock-based compensation, fell to $8.0 million from $10.5 million.

Percentage changes are calculated from the rounded figures provided by the company.

NERLYNX Demand Supported Product Revenue, but Royalties Fell

NERLYNX accounted for all $54.1 million of Puma’s net product revenue. Management said increased year-over-year U.S. demand supported sales, while a higher-than-expected gross-to-net adjustment related to increased Medicaid and 340B sales reduced the benefit. Some sales to commercial partners outside the United States were also delayed from the third quarter into the fourth quarter.

The product revenue increase was partly offset by the $1.6 million decline in royalty revenue. In addition to normal royalty activity, the quarter included the $2.1 million negative accounting adjustment related to generic NERLYNX market share in China.

Puma also continued expanding the alisertib clinical program. It initiated the Phase II ALISCA-Lung2 trial in September 2026 and continued enrolling the ALISCA-Breast1 and ALISCA-Lung1 studies. Planned milestones include updated ALISCA-Breast1 data in December 2026, discussions with global regulators about a potential Phase III breast cancer trial design in the first half of 2027, and updated ALISCA-Lung1 data during 2027.

Higher R&D and Cost of Sales Compressed Margins as Cash Flow Improved

Cost of sales rose to $15.2 million from $12.2 million, primarily because of higher product sales to an international partner. R&D expense increased to $18.3 million from $15.9 million, while SG&A expense declined slightly to $16.3 million from $16.8 million.

For the first nine months of 2026, Puma attributed the $11.8 million year-over-year R&D increase mainly to $8.9 million of additional clinical trial expense associated with alisertib and approximately $2.9 million of higher internal R&D expense, primarily employee compensation. This increased investment helps explain why quarterly operating income fell faster than revenue changed.

The cash-flow picture moved in the opposite direction from reported earnings. Quarterly operating cash flow increased to $14.6 million from $9.7 million, while cash, cash equivalents, and marketable securities reached $108.5 million at September 30, 2026, compared with $97.5 million at the end of 2025. Working capital increased to $105.7 million from $81.4 million over the same period.

The current portion of long-term debt was zero at quarter-end versus $22.5 million at December 31, 2025. Puma paid down debt principal in May 2026, and the company said lower interest expense was the main reason year-to-date other income improved. In Q3, total other income was $0.9 million, compared with $0.4 million of other expense a year earlier.

Financial Guidance

Puma raised its full-year net income outlook to $20 million-$22 million from $17 million-$20 million. At the same time, it lowered the royalty revenue range, narrowed total revenue guidance by reducing the upper end, and raised its expected gross-to-net adjustment.

The outlook excludes potential adjustments related to the tax valuation allowance. The higher gross-to-net range indicates that Medicaid and 340B mix will remain an important factor in converting NERLYNX demand into reported net product revenue.

Recent Insider Transactions

The supplied insider dataset shows 239,000 shares purchased across eight transactions and 208,564 shares sold across 10 transactions during the latest six-month period. That represents net purchases of 30,436 shares, or 0.40%, while insiders held a combined 7.93 million shares.

The 10 latest individual records consist of nine sales and one derivative exercise or conversion. All were reported as direct transactions; the records alone do not establish insiders’ views on Puma’s outlook.

Risks Investors Need to Watch

• Dependence on NERLYNX: All quarterly product revenue came from NERLYNX, leaving Puma’s commercial results concentrated in a single product.
• Gross-to-net pressure: Increased Medicaid and 340B sales produced a higher-than-expected deduction from gross sales, and Puma raised its full-year gross-to-net assumption.
• Royalty and partner-sales volatility: The China-related accounting adjustment reduced royalty revenue, while delayed sales to international partners shifted revenue between quarters.
• Rising development spending: Greater alisertib clinical activity increased R&D expense and contributed to lower operating profit. Future clinical data and regulatory discussions remain important execution milestones.

Summary

Puma Biotechnology generated higher NERLYNX product revenue and stronger operating cash flow in Q3 2026, but lower royalties and increased cost of sales and R&D spending reduced operating income and EPS. The raised full-year net income outlook is constructive for reported profitability, while the higher gross-to-net assumption and reduced royalty forecast remain important constraints. The next points to monitor are fourth-quarter international partner sales, continued U.S. NERLYNX demand, and progress across the alisertib trials.